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In 2012 over two thirds of US adults aged 20 years or older had a Body Mass 
Index (BMI) at or above 25, rendering them overweight or obese (Ogden). Widespread 
obesity in America is a relatively new phenomenon; in a thirty-year period, from 1971 
to 2001, there was a 30% increase in adult obesity, generally defined as a BMI at or 
above 30 (Vasan). In 2005, obesity surpassed cigarette smoking as the most common 
preventable cause of early mortality (Larson). 
Medical conditions associated with obesity have shown concomitant increases in 
prevalence. Obese individuals have a higher propensity to develop a host of 
simultaneous chronic medical conditions, or comorbidities, including cardiovascular 
disease, metabolic conditions such as type II diabetes, hypertension, infertility, chronic 
pain, gastrointestinal disease, various pathologies of the liver, and numerous cancers 
(DynaMed, Bhaskaran, Renehan). Some obesity-related disorders such as 
atherosclerosis, hypertension, and a variety of conditions related to metabolism, can be 
asymptomatic in initial stages. Symptoms arising from these conditions commonly 
manifest in only advanced phases when they are often more difficult to treat.  
 In particular, non-alcoholic simple steatosis (SS) of the liver, an obesity-related 
complication, is common but difficult to diagnose and may progress to more severe 
liver pathologies (Tucker). SS is characterized by abnormal accumulation of fat in liver 
cells, hepatocytes, which is asymptomatic in early stages. It is estimated that 20% or 
more of all American adults are living with SS, but prevalence increases to 70 – 80% in 
obese populations. Scientists expect rates of SS incidence to continue to rise (Lall). 





disease (NAFLD), which encompasses a more severe series of liver pathologies, and is 
a known risk factor in the development of hepatocellular carcinoma (HCC), the most 
common cancer of the liver.  
Given the current high frequency of obesity and its association with liver 
pathologies such as NAFLD and HCC, uncovering the mechanisms of liver disease 
establishment and progression has been a recent focus in research (Tucker). The 
purpose of this thesis is to present a literature review of recently published research 
articles examining the relationship between obesity and HCC. Several mechanisms that 
have been proposed to underlie the development of HCC as a comorbidity to obesity 

















The focus of the written portion of this thesis is to present a critical analysis of 
recently published, peer-reviewed journal articles examining the relationship between 
obesity and hepatocellular carcinoma. A literature search was performed for relevant 
articles published through January 2015 using PubMed. Search terms included obesity, 
hepatocellular carcinoma, Non-alcoholic Fatty Liver Disease, and cirrhosis. 
Approximately 138 articles published within the dates of interest were reviewed.  15 
articles were selected for thorough analysis. Priority was given to articles discussing 
well-executed studies most relevant to the topic. The results of these studies are 
discussed in a systematic review. The analysis aims to summarize what is known and 















Anatomy and Basic Functions of the Liver  
The liver is the largest internal organ of the body, positioned in the upper right 
quadrant of the abdominal cavity, inferior to the diaphragm (Guyton 873). The liver is a 
discrete organ but serves numerous critical roles including regulation of multiple 
metabolic functions, storage of blood and nutrients, blood purification, cholesterol 
synthesis, and production of bile and coagulation factors (Guyton 873). The liver plays 
a key role in carbohydrate metabolism and blood glucose regulation to assure a steady 
supply of glucose to the brain. At rest, blood glucose concentration dictates whether 
glucose reserves are synthesized or degraded in the liver. This activity is mediated by 
glucose flux through enzymatic pathways that are controlled by hormone signaling to 
maintain a suitable range of blood sugar (Voet 772). In addition to regulating 
carbohydrate metabolism, the liver plays a critical role in processing ingested fats. Liver 
cells are rich in mitochondria, which are cellular components responsible for generating 
energy through a particular type of metabolism that requires oxygen. This metabolic 
process, termed oxidative phosphorylation, uses fatty acids liberated from liver cells to 
generate energy. If energy demand is low, the liver forms excess ingested fatty acids 
into triglycerols. The latter are transported to adipose tissue, or fat, for storage via 
lipoproteins, units of lipid and protein molecules that allow non-soluble fat molecules to 
travel through the body’s aqueous environment (Voet 773). Another feature of the liver 
related to metabolism is its capacity to store vitamins and minerals, such as vitamin D 





The anatomy of liver circulation is critical to the blood filtering function of the 
liver. Chemical digestion of food in the small intestine allows nutrients to be absorbed 
into capillaries adjacent to digestive tract walls. The nutrient-rich, semi-oxygenated 
blood flows through one main vein for entry into the liver. This main vein divides into 
smaller and smaller diameter vessels in the liver until each liver cell is positioned 
adjacently to a capillary (Moore, 237). Liver tissue is highly vascularized as a result of 
this organization. Blood processed by liver cells undergoes purification by 
macrophages, white blood cells that function as part of the immune system to remove 
bacteria of gut origin. The liver also processes and clears pharmaceuticals, toxins, and 
retired red blood cells. Blood filtered by liver cells collects into central veins and 
eventually flows into the hepatic veins and ultimately into the inferior vena cava, which 
supplies de-oxygenated blood to the right atrium of the heart.  
Formation of bile is another important function of the liver. Bile is stored in the 
gallbladder, a relatively small sac-like organ that sits just below the liver. Bile is 
released into the small intestine upon consumption of meals with high fat content and 
acts as an emulsifying agent; it allows fatty molecules to easily move through aqueous 
environments, which subsequently enables breakdown of dietary fat. These lipids are 
then able to form into lipoprotein assemblies as an initial step in triglyceride distribution 
to tissues of the body. This process is related to regulation of cholesterol levels, another 
vital function of the liver. Liver cells contain enzymes necessary for synthesis of new 
cholesterol if too little is available in the diet. Distribution of newly synthesized 
cholesterol or cholesterol derived from the diet is regulated by the liver as is the 





The liver can also act as a reservoir for blood under situations of backpressure 
from the heart. Healthy liver tissue can expand so that up to one extra liter of blood can 
be stored, beyond the nearly half liter of blood volume typically held in the liver in 
adults (Guyton 838).  
A well-functioning liver is vital to health as it is responsible for many bodily 
processes occurring continuously and simultaneously. The multifunctional nature of the 
liver becomes apparent when the liver malfunctions (Guyton 837). Liver damage often 
alters many processes, which can result in a combination of different symptoms. This 
has major implications for individuals with liver damage.  
Obesity: Classification and Associated Complications 
Obesity is a medical condition that indicates excess fat accumulation, which 
may have adverse effects on health. Obesity most often develops as a result of chronic 
excess caloric intake and lack of physical activity. It is well established that a high BMI 
is associated with an increased risk for numerous cancers including cancers of the liver 
(Bhaskaran, Renehan).  
Body mass index (BMI) is a ratio of height and weight used as a clinical tool to 
assess body fat and classify individuals as underweight, normal weight, overweight, and 
obese. The formula for BMI is . Individuals with a BMI at or above 25 are 
classified as overweight. A BMI at or above 30 is considered obese (USA). BMI does 
not take body composition into account, and thus may misclassify individuals. Various 
tissue types have unique densities and therefore have different weights per unit volume. 





who have a high muscle to fat ratio, like bodybuilders, are typically heavy relative to 
their height and may therefore be classified as overweight by BMI. Other simple 
methods of assessing obesity are used, such as height to waist circumference ratio. 
However, due to its ease of use and general accuracy, BMI remains a widely used figure 




















Obesity and Nonalcoholic Fatty Liver Disease 
Non-Alcoholic Fatty Liver Disease (NAFLD) is a term encompassing a group of 
conditions related to the abnormal accumulation of lipids within small vessels of the 
liver, unrelated to increased alcohol consumption (Lall).  Obesity along with other 
metabolism-related conditions such as diabetes and metabolic syndrome have been 
found to be risk factors for NAFLD.  The term NAFLD includes any stage in this 
pattern of associated conditions: nonalcoholic simple steatosis (SS), nonalcoholic 
steatohepatitis (NASH), chronic liver fibrosis, and liver cirrhosis. Because it describes 
such a wide spectrum of diseases, NAFLD has appropriately been described as “the 
lynchpin between steatosis and cirrhosis in the spectrum of nonalcoholic fatty liver 
disorders” (Farrell, Lall).  
Obesity and NAFLD are strongly correlated; 70 – 80% of obese individuals 
have the first stage of NAFLD (Lall). Liver cells processing large quantities free fatty 
acids over long periods of time eventually cannot maintain the level of activity required 
and start to accumulate abnormally high levels of intracellular triglycerides. This 
process can eventually result in the development of SS, the abnormal accumulation of 
excess triglycerides and other fats in liver cells.  
The progression from SS to NASH, inflammation of the liver due to fat 
accumulation, has a generally accepted mechanism, but many details remain unclear. 
When levels of triglycerides are consumed that chronically exceed demand by cellular 
processes, fat accumulates in deposits around internal organs and under the skin. Large 





metabolism of fats and carbohydrates, which increases the rate of fat accumulation in 
the liver (Rinella). SS can progress until excessive levels of triglycerides accumulate 
within liver cells and cause the release of oxidized lipids, which then induces an 
inflammatory response. As fat continues to accumulate, the inflammation cascade fails 
to cease, damaging liver cells. If left unresolved, acute NASH can develop, which can 
have significant consequences on liver function. When liver cells sustain long-term 
inflammation from NASH, liver tissue eventually becomes scarred and hardened, 
causing fibrosis. The progression of the NAFLD spectrum is dynamic and largely 
reversible in early stages; however when liver fibrosis progresses further to liver 
cirrhosis, damage to the liver is irreversible. As the degree of liver cirrhosis increases in 
patients, the poorer their prognosis becomes. NAFLD initiated cirrhosis can be fatal and 
is predicted to become the most frequent cause of liver transplant (Rinella). 
Obesity is not the only risk factor in the development of liver pathology. Many 
medical conditions are associated with liver inflammation and cirrhosis, such as viral 
hepatitis. There is also evidence for a heritable factor for the development of NAFLD. 
Small differences in genes encoding proteins important in metabolic pathways of lipids 
are associated with a genetic predisposition to the development of NAFLD (Agrawal). 
Diagnosis of Nonalcoholic Fatty Liver Disease 
Diagnosing NAFLD poses challenges, as disease progression is dynamic and 
patients tend to be asymptomatic, especially in early stages. Early symptoms are usually 
vague, such as abdominal discomfort, fatigue, dyspepsia and nausea. Liver biopsy is the 
only method used to definitively diagnose the stage of NAFLD. However, there are 





diagnosis. These techniques include various biomarkers, levels of particular molecules 
and enzymes derived from blood chemistry, and several forms of imaging. Predictive 
assays are also used, which are equations that take multiple variables such as BMI and 
biomarker levels into account to yield a value that indicates a patient’s risk for a 
particular stage of NAFLD.   
Clinicians can also test multiple biomarkers simultaneously in a liver function 
panel. Levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), 
two biomarkers tested in liver fibrosis panels, are commonly elevated in NAFLD. These 
two enzymes are normally found at highest concentrations in the liver and in low 
concentrations in the blood. The liver releases these proteins into the blood upon 
sustaining damage due to fatty accumulation and cirrhosis, so a finding of high ALT 
and AST in the blood suggests possible NAFLD. Though ALT levels are normally 
elevated in patients with NAFLD, the correlation between high AST and NAFLD is 
weak. Gamma glutamyl transferase (GGT) is another enzyme that is commonly tested 
as an indicator of NAFLD in liver function panels, but is elevated in only approximately 
half of individuals with NAFLD (Oliviera 3). Although some biomarker levels are 
weakly correlated with NAFLD, if multiple abnormal tests results are observed in a 
liver function panel, it may serve as useful diagnostic information. Biomarkers also 
enable clinicians to observe levels of particular indicators over time. For example, one 
commonly used guideline states that if AST and ALT levels are elevated by 1.5 times 
normal levels for over six months, clinicians may elect to perform a liver biopsy for 





function tests are sometimes found to be completely normal in individuals with early 
stages of NAFLD (Agrawal).  
Several forms of imaging are used to diagnose NAFLD including ultrasound, 
magnetic resonance imagining, magnetic resonance elastography, and vibration-
controlled transient elastography (fibroscan). Some imaging techniques can accurately 
recognize differences between stages of SS and steatohepatitis. Fibroscan imaging has 
been shown to accurately identify and distinguish fibrosis and cirrhosis of the liver 
(Rinella). Fibroscan measures the speed of waves moving through liver tissue, which 
can give insight into the stage of fibrosis (Oliviera 3). Ultrasound sensitivity decreases 
with increasing BMI, and thus obese populations can be under-diagnosed (Oliviera 3). 
The combination of new imaging techniques with blood chemistry biomarkers improves 
the accuracy of NAFLD diagnosis. 
Predictive assays are tools employed to assess the risk of NAFLD. The Fatty 
Liver Index, NAFLD fibrosis score, and NAFLD activity score are examples of 
predictive assays used to assess risk. These calculations bring together a number of 
different values from a patient’s chart such as BMI, ALT and ALS levels, and age in a 
calculation that can estimate the risk of NAFLD.  However, there is not enough 
evidence to prove that the latest assay models are accurate. The NFS score has not yet 
been approved as a diagnostic tool of NAFLD, although use of this value as an indicator 
of liver fibrosis has been suggested.  
Liver biopsy is the most definitive method to assess liver pathology. However, 
liver biopsy is invasive and carries a risk for infection or other complications. 





tissue may still be missed. In sum, despite many methods available to diagnose 
NALFD, drawbacks of each method coupled with mild or absent symptoms associated 
with disease progression lead to significant under-diagnosis (Tucker).  
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma 
Hepatocellular carcinoma (HCC) is the most prominent form of liver cancer. 
HCC has been described as one of the “most lethal human malignancies, due to the 
difficulty of early detection, chemoresistance, and radioresistance, and is characterized 
by active angiogenesis and metastasis, which account for rapid recurrence and poor 
survival (Yang).” HCC is the most common cause of death in individuals with liver 
cirrhosis, and its frequency is predicted to rise. A five-year study done between 2001 
and 2006 saw a 3.5% increase in incidence of HCC in the United States  (Dynamed).  
NAFLD is a risk factor for HCC. The pathophysiology of NAFLD and cirrhosis 
related to hepatocellular carcinoma is complex. Multiple mechanisms have been 
suggested leading to the correlation. The Multiple Hits Theory posits that disease 
progression can be due to the collective effect of several factors including genetic, 
epigenetic and environmental causes (Corte). One mechanism emanating from the 
Multiple Hits Theory is the upregulation of peroxisome proliferator-activated receptor 
alpha (PPARα). Accumulation of free fatty acids in hepatocytes in NAFLD eventually 
leads to cell damage and release of oxidized lipids. PPARα detects the accumulation of 
free fatty acids and signals for enzymes to increase rate of their disposal. Chronic 
activation of the PPARα receptor has been demonstrated to accelerate the development 





Misregulation of normal cellular pathways in hepatocytes can lead to abnormal 
rates of cell proliferation that can eventually develop into hepatocellular carcinoma.  
There are many factors that can cause regulation of cellular pathways to become faulty. 
For example, the presence of abnormally high concentrations of growth factors, 
molecules that stimulate cell growth, may increase the rate of biochemical pathways 
that induce abnormally high cellular proliferation, which may initiate tumor growth. 
Additionally some cellular receptors emit constitutive signaling upon sustaining 
damage, which may stimulate an increase in rate of these tumorigenic pathways. 
Apoptosis, programmed cell death, occurs at a normal rate in cells, but damage to 
pathways leading to apoptosis can reduce cell death rates. This process can also 
contribute to increased rates of cell proliferation.  
Insulin resistance is another critical mechanism in the Multiple Hits Theory of 
HCC development. In obese patients with NAFLD, chronic accumulation of fat in the 
liver has been shown to increase insulin resistance (Oliviera 8). Insulin is a peptide 
hormone critical to the maintenance of blood glucose levels. The pancreas releases 
insulin into the blood in conditions of high blood glucose, which normally allows 
glucose to enter liver and muscle cells for metabolism. When insulin receptors become 
resistant to insulin, glucose cannot enter cells. This causes glucose to accumulate to 
high levels in the blood, which causes the pancreas to secrete higher levels of insulin to 
reduce blood glucose. This results in hyperinsulinemia, high levels of insulin in the 
blood relative to glucose. Hyperinsulinemia causes a decrease in production of insulin-
like growth factor-1 binding protein (IGFBP-1), an inhibitor of insulin-like growth 





1 receptors on liver cells activate strong anti-apoptotic, signals in the presence of IGF-1 
(Weinberg, 386). Therefore, insulin resistance can lead to strong signals that inhibit 
programed cell death, which ultimately promotes tumorigenesis, the development of 
cancerous tumors.  
Insulin resistance also causes the body to rely more heavily on the metabolism 
of fats instead of carbohydrates due to the inability of cells to uptake glucose. The liver 
facilitates this transition by liberating fatty acids to generate energy through a metabolic 
process that requires oxygen. Heavy reliance on this type of metabolism can cause an 
accumulation of reactive oxygen species (ROS) in liver cells, which causes hepatic 
oxidative stress (Oliviera). ROS can directly damage cellular components like 
mitochondria and DNA. Chronic low-grade inflammation can result from cellular 
damage due to ROS accumulation in liver cells. Chronic inflammation promotes the 
development of fibrosis and cirrhosis, which have been shown as major risk factors in 
the development of HCC. 
Obesity and Hepatocellular Carcinoma 
Obese individuals with a BMI at or above 30 have a four times higher risk of 
developing HCC over those with a BMI less than 30 (Chen). Obese individuals have a 
chronic low-grade inflammation response, which promotes the development of many 
cancer types including HCC (Perumpail). High levels of adipose tissue signal the 
release of proinflammatory cytokines, small proteins that signal an inflammation 
response. These are important for the continuation of the inflammatory response and 
mediating tumor-promoting functions such as inhibiting apoptosis. Chemical signals 





Release of pro-inflammatory cytokines and activation of cancer-causing pathways are 
signals for cell growth and division for tissue healing, but chronically elevated levels 
are associated with HCC development (Perumpail). High levels of adipose tissue in 
obese individuals also elevate levels of leptin, a hormone that regulates the body’s level 
of excess fat by inducing the feeling of satiety. High leptin levels contribute to the 
inflammatory response and may promote the growth of new blood vessels, which is a 
critical process to tumor development.  
Another proposed mechanism that may contribute to the progression HCC is the 
effect of obesity on gut bacterial flora. Obesity has been shown to cause overgrowth of 
gut bacteria and a simultaneous increase in permeability of intestinal wall cells. This 
imbalance causes a higher concentration of bacteria to enter liver circulation. Increased 
gut bacteria can overwhelm the filtration mechanisms of hepatocytes, which can 
contribute to chronic inflammation and fibrosis (Corte).  
Prevention and Treatments  
Currently there are no FDA-approved drugs available to treat nonalcoholic 
steatosis. Two pharmaceuticals aimed at treating NAFLD have been tested in clinical 
trials; however, both were effective in fewer than 50% of the participants (Rinella). 
Probiotics and vitamin E supplements have been suggested to help slow the progression 
of NAFLD, but there is no evidence that demonstrates a benefit.  
Lifestyle modifications designed to reduce risk factors of developing NAFLD 
are the main way clinicians manage at-risk patients. Weight loss is extremely helpful to 
diminishing the risk of developing NAFLD, hepatocellular carcinoma, and other 





composition has decreased the risk of more severe conditions like cirrhosis and HCC 
(Agarwal). These studies also report that the loss of 3-5% of body weight in obese 
persons can reverse SS. Later stages of NAFLD that involve fibrosis and cirrhosis 
require the loss of more than 5% of body weight to demonstrate significant 
improvement. Weigh loss has also been shown to decrease levels of inflammatory 
cytokines, which reduce chronic inflammation and risk of HCC (Perumpail). Exercise 
may improve liver function independent of weight loss by normalizing liver enzyme 
levels and preventing insulin resistance (Oliviera 8). Bariatric surgery is cited frequently 
as an option to treat NAFLD. Individuals who underwent bariatric surgery as a means 
of weight loss showed improvement in liver histology even in cases of advanced 
















The connection between obesity and hepatocellular carcinoma is complex, and 
many details have yet to be determined. However researchers agree on some basic 
pathways that link the two medical conditions. The Multiple Hits Theory proposes 
several pathways that contribute to disease progression, which is the most accurate and 
widely agreed upon model for HCC development among researchers. Chronic 
inflammation and insulin resistance in obese individuals appear to contribute to the 
development of HCC. There is a high likelihood that obese individuals exist somewhere 
on the spectrum on NAFLD, which is another strong indicator of risk for developing 
HCC.  
There is an ongoing discussion among clinicians on the challenges that come 
with diagnosing individuals on the spectrum NAFLD. Healthcare providers have 
limited tools for diagnosis and treatment of NAFLD. Studies agree that encouraging 














With obesity as common as it is today and serving as a strong risk factor in the 
development of many conditions like NAFLD and HCC, understanding the mechanisms 
that relate these conditions is essential for designing treatments. Recently published 
articles on obesity and HCC have elucidated many mechanisms that contribute to 
disease development. Diagnosis of NAFLD poses a surprising number of challenges to 
clinicians. Continued development of reliable techniques will be beneficial for early 
detection and intervention. There currently are few pharmaceutical options available to 
treat and prevent NAFLD. Pharmaceuticals that slow progression of NAFLD should be 










































































































































Appendix B: BI123 Class Notes 
The Relationship Between Obesity and Cancer:  
 
Media coverage of threatening diseases like Ebola causes the public to 
become very concerned. However, far more people in the US die from largely 
lifestyle-mediated causes such as use of tobacco, high alcohol consumption, 
and obesity. Obesity is a risk factor for the development of cancer, which is the 
main topic of this presentation.  
 
Obesity Today 
 Obesity is clearly a large and growing problem in the United States today.  
Over two thirds of adults were classified as overweight or obese in 2012. 
 From 1971 to 2001, there was a 30% increase in adult obesity. 
 Obesity often defined as Body Mass Index (BMI) above 30. 
 
Body Mass Index (BMI) 
 The equation for BMI is:  
BMI is a widely used tool in medicine and research used to classify the 
severity of obesity. However, BMI is not always a perfectly accurate gage of 
extra body fat. For example, Arnold Schwarzenegger, former Mr. Universe, 
would be considered obese using this calculation. Schwarzenegger was just 





a BMI of over 30 is considered obese. The range of BMI from 18.5 to 24.9 is 
considered normal weight. 
 
Obesity-Related Complications  
Obesity affects all body systems in complex ways and has a big impact on 
metabolism. Obesity is a risk factor for the development of many cancers.   
 
Cancer-Obesity Correlation  
 
This graph examines relative risk of various cancers in obese men. This 
graph has brought together information from many studies. On the Y-axis, there 
are different cancer types and BMI at which researchers examined. The X-axis 
represents relative risk and confidence intervals (CI), which shows how 
statistically significant the values are. For example, men with a BMI of 35 have 
about double the risk of developing stomach cancer relative to men with a BMI 





getting cancers that affect organs of the gastrointestinal tract at high BMIs.    
 
This examines relative risk of various cancers in obese women. A similar 
trend between obesity and risk of cancer is observed in women for different 
cancer types than men. Notice that obese women are at especially higher risk 
of developing cervical and uterine cancers, which is related to high levels of 
estrogen as explained further below.  
 
Cancer-Obesity Causation  
There are many complex physiological mechanisms that contribute to 
causation. Fat tissue produces high levels hormones that promote cancer 
development. For example, obesity can induce high levels of estrogen 
production, which is associated with increased risk of breast, uterine, and 
cervical cancers. Another molecule, leptin, is higher in obese populations and 
promotes cell proliferation. Increased levels of insulin also promote the 





other likely confounding mechanisms exist. For example, low-grade chronic 
inflammation in obese individuals causes release of inflammation mediators that 
yield mutations in important genes. These mutations give cells survival 
advantage, but if too many accumulate, tumor development can occur.   
 
Obesity Influences Metabolism  
 Metabolism: The chemical processes by which a plant or an animal uses 
food, water, etc., to grow and heal and to make energy.  
Metabolic rate is how quickly the body is using food to produce energy.  
 
Insulin and Insulin Resistance 
Cells rely on the sugar glucose for energy (Metabolism) 
 Insulin is released into bloodstream by the pancreas when blood glucose is 
high Insulin signals cells to uptake glucose. However, if receptors become 
resistant to insulin, glucose cannot enter cells. In response to even higher 
blood glucose, insulin production increases.  
 Hyperinsulinemia: high levels of insulin in the blood relative to glucose 
 High levels of insulin stimulate the production of some mitogens.  
 A mitogen is a chemical that promotes cell growth 
 Hyperinsulinemia causes more of a mitogen called insulin-like growth factor-







Type II Diabetes 
 Type II Diabetes is a medical condition in which individuals become resistant 
to insulin. Obesity is a risk factor for type II diabetes.  
Research has indicated that some cancers including liver, pancreas, and 
breast cancer appear more commonly in individuals with type II diabetes. “The 
relative risks imparted by diabetes are greatest (about twofold or higher) for 
cancers of the liver, pancreas, and endometrium, and lesser (about 1.2–1.5 




Basic functions:  
 Large regulator of metabolism 
 Storage of blood and nutrients 
 Blood purification 
 Cholesterol synthesis and regulation 
 Production of bile and coagulation factors 
This is only five, but the liver performs hundreds of functions! 
 
Hepatocellular Carcinoma (HCC) 
 Hepatocellular Carcinoma (HCC) is the most common type of liver cancer. 





liver cancer occurs it can be hard to detect because the liver has so many 
functions.  
Insulin resistance causes our metabolism to shift from sugar to fat breakdown 
for energy. High levels of free fatty acids accumulate in the blood. Abnormal fat 
accumulation occurs in liver cells.  
 Fat accumulation in liver cells can cause inflammation, which eventually 
causes scarring and hardening.  Inflammation and scarring cause release of 
chemicals that promote tissue healing.  
 One process of healing is cell proliferation. This is a step towards HCC.  
 
Prevention  
 Weight Loss – Weight loss has been shown to reduce the risk of cancer.  
 Diet – Consuming a healthy diet rich in antioxidants has also been 
shown to reduce the risk of cancer. 
 Exercise – Cardiovascular exercise can help stabilize insulin levels, 
which can contribute to its cancer risk-reducing affect. 
 Stop Smoking! – Smoking doesn't only promote lung cancer! As we have 
seen, there are many complex physiological mechanisms that contribute 
to the development of cancer. Obesity and smoking are big cancer 








Appendix C: BI123 Class Handout  
The Relationship Between Obesity and Cancer 
 
 
 From 1971 to 2001, there was a ________________ increase in adult obesity. 
 Obesity often defined as Body Mass Index (BMI) above ________________. 
 The equation for BMI is: ______________________ 
 Metabolism: The _____________ processes by which a plant or an animal uses 
food, water, etc., to grow and heal and to make __________________ 
 _______________ is released into bloodstream by the _______________ when 
blood glucose is high 
 Hyperinsulinemia: high levels of _________-______ in the blood relative to 
___________________ 
 High levels of _____________ stimulate the production of some ____________. 
 A mitogen is a chemical that promotes ___________________ 
 _______________ causes more of a mitogen called _____________________ to 
become available, which promotes ______________________. 
 __________________ is a medical condition in which individuals become resistant 
to insulin. 
 ___________________ (HCC) is the most common type of liver cancer. 
 Fat accumulation in _________________can cause ___________________, which 
eventually cause ________________ 
 Inflammation and scarring cause release of chemicals that promote 
_____________________. One process of healing is cell proliferation. This is a 
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